Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
BMC Cancer|July 2, 2020
Cardio-toxicity among patients with sarcoma: a cardio-oncology registrySivan Shamai, Zach Rozenbaum, Ofer Merimsky, et al.Plos One|September 23, 2015
CD24 and APC Genetic Polymorphisms in Pancreatic Cancers as Potential Biomarkers for Clinical OutcomeSivan Shamai, Ilana Nabiochtchikov, Sarah Kraus, et al.Gynecologic Oncology|July 16, 2013
Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma--a retrospective studyTamar Safra, Sivan Shamai, Julia Greenberg, et al.Cancer|June 24, 2023
Association between diabetes mellitus and reduced efficacy of pembrolizumab in non-small cell lung cancerYasmin Leshem, Yardenna Dolev, Nava Siegelmann-Danieli, et al.Clinical Research in Cardiology : Official Journal of the German Cardiac Society|October 27, 2022
The predictive value of high sensitivity troponin measurements in patients treated with immune checkpoint inhibitorsBarliz Waissengein, Bian Abu Ata, Ofer Merimsky, et al.Clinical Research in Cardiology : Official Journal of the German Cardiac Society|April 17, 2020
Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditisShira Peleg Hasson, Benjamin Salwen, Ayelet Sivan, et al.International Journal of Cardiology|December 8, 2023
The prognostic value of beta-1 blockers in patients with non-small-cell lung carcinoma treated with pembrolizumabYasmin Leshem, Tal Etan, Yardenna Dolev, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 5, 2021
Cancer Therapeutics-related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied ManifestationShira Peleg Hasson, Joshua Arnold, Ilan Merdler, et al.Journal of Clinical Medicine|November 9, 2024
Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung CancerWalid Shalata, Sameh Daher, Natali Maimon Rabinovitch, et al.The Oncologist|March 19, 2022
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world DataMor Moskovitz, Elizabeth Dudnik, Sivan Shamai, et al.Pageof 3